SCHEMBL982012

SCHEMBL982012

COCCOc1nc(C(=O)O)c(-c2cccc(Cl)c2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 2/20 0.44
TP53 P04637 1/20 0.43
MALT1 Q9UDY8 1/20 0.41
MDM2 Q00987 4/20 0.41
KMO O15229 2/20 0.40
MAPK14 Q16539 1/20 0.40
VEGFA P15692 1/20 0.40
FLT1 P17948 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
EGLN3 Q9H6Z9 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KMT2A Q03164 1/20 0.39
F2RL3 Q96RI0 1/20 0.38
LTB4R Q15722 1/20 0.38
PTGER4 P35408 1/20 0.38
CTSA P10619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982476 0.87 TRPM8 (0.46) PIN1MDM2KMOMAPK14TRPM8
SCHEMBL984661 0.86 PIN1 (0.49) PIN1MDM2KMOTRPM8NPC1
SCHEMBL11916732 0.82 HRH3 (0.46) TP53MALT1TRPM8KMT2AF2RL3
SCHEMBL2127594 0.77 HCRTR1 (0.40)
SCHEMBL271164 0.76 PIN1 (0.59) PIN1MDM2KMT2A
SCHEMBL2930814 0.76 PIN1 (0.46) PIN1POLQ
SCHEMBL3009703 0.75 PIN1 (0.50) PIN1MDM2KMONPC1POLB
SCHEMBL1971006 0.74 KDM4E (0.51) PIN1MDM2KMONPC1RAB9A
SCHEMBL984930 0.73 PIN1 (0.49) PIN1TP53MDM2KMONPC1
SCHEMBL985026 0.73 PIN1 (0.46) PIN1MDM2KMOMAPK14TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236801-B2 2-aza-bicyclo[2.2.1]heptane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-08-07 US disclosed
EP-2247586-B1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-04-25 EP disclosed
US-20110009401-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-01-13 US disclosed
EP-2247586-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-11-10 EP disclosed
WO-2009104155-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009401-A1 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES HCRTR2, HCRTR1, HCAR2 PIN1 3660/4885TP53 4861/4885MALT1 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.